JP5829870B2 - 持続放出製剤 - Google Patents
持続放出製剤 Download PDFInfo
- Publication number
- JP5829870B2 JP5829870B2 JP2011196883A JP2011196883A JP5829870B2 JP 5829870 B2 JP5829870 B2 JP 5829870B2 JP 2011196883 A JP2011196883 A JP 2011196883A JP 2011196883 A JP2011196883 A JP 2011196883A JP 5829870 B2 JP5829870 B2 JP 5829870B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- complex
- protein
- sustained release
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
実施例1は、ペプチドB−PGG塩(ペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)対PGGの1:1モル比)の製造の説明を提供する。PGG94mgをNaOH溶液2ml(0.10から0.20NのNaOH濃度)に溶解し、次にこれを0.2μmフィルターでろ過することによってPGGの原液を作製した。PGGの原液(1.56mL)に、水0.8mL中のペプチドB酢酸塩109.4mgの溶液を攪拌しながら連続的に添加し、沈殿物を形成させた。遠心分離によって沈殿物を回収した。
ペプチドA−PGGとタンニン酸の塩を、実施例1のペプチドB−PGGと同様にして作製した。ペプチドAは、アセチル Lys Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpgであった。
以下の表1及び2は、水中及びPBS中での、タンニン酸及びPGGとペプチドA(アセチル Lys Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)及びペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)の塩のペプチド含量及び溶解度を列挙する。データは、PGGペプチド塩がタンニン酸塩よりも高いペプチド含量を有することを示した。PGG沈殿物はタンニン酸塩よりも高いPBS溶解度を有する。
ペプチドB−PGG塩の収率、ペプチド含量及び溶解度への塩形成pH(すなわちNaOHの濃度レベル)の影響の試験を実施した。pH7.0、7.2、7.6及び8.6の4つのペプチドB−PGG塩を作製し、単離した。次に、水中及びPBS中でのこれらの溶解度、及びまたこれらのペプチド含量も測定した。これらの結果は、塩形成の間のpHが上昇すると共に水溶解度、塩形成の収率及びペプチド含量が上昇することを明らかにする(表3)。
この実施例は、ラットにおけるペプチドB/PGG及びペプチドB/タンニン酸塩の持続放出を述べる。ラット薬物動態(PK)試験を、TRIS緩衝液に懸濁したペプチドB/PGG塩及びペプチドB/タンニン酸塩;及び対照群としてペプチドB酢酸塩のPBS溶液の単回皮下注射(10mg/kg用量)によって実施した。PK結果は、pH7.0で作製したペプチドB/タンニン酸塩及びペプチドB/PGG塩に関して1週間の持続放出を示した。しかし、pH7.6及び8.6で作製したペプチドB/PGG塩は、pH7.0で作製した塩(2週間まで)に比べてより短い放出期間(約2−3日間)を示した。
ペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)のPGG塩の純粋なアノマー(β−PGG)及びアノマーの混合物(α+β−PGG)を、実施例1で述べたのと同様の方法によって作製した。これらの塩の水溶解度に有意差はなかった。水溶解度に基づき、これらの塩についてのインビボ持続放出期間は類似すると予想される。
以下の実施例は、持続放出に関する動物薬物動態(PK)試験において検討した、ペプチドとの塩を作製するためのEGCGの使用を述べる。EGCG184mgを0.2N NaOH 2ml中に溶解し、次にこれを0.2μmフィルターでろ過することによってEGCG(Sigma−Aldrich)の原液を作製した。EGCGの原液(1.4mL)に、水1.2mL中のペプチドB(DOrn Lys Arg Pro Hyp Gly Cpg Ser Dtic Cpg)の酢酸塩138mgの溶液を攪拌しながら緩やかに添加した。生じた懸濁液を室温で約10−15分間攪拌した。遠心分離後、上清を傾瀉し、沈殿物を水1mLで洗った(遠心分離と上清の傾瀉ごとに3回ずつ)。沈殿物を真空下に約30−35℃で約20時間乾燥して、ペプチドB−EGCG塩218mg(88%)をオフホワイト色の粉末として得た。
Claims (2)
- アミノ酸20以下のペプチドの溶液と没食子酸エピガロカテキン(EGCG)の溶液とをpH6.5〜8.6にて混合して、前記ペプチドと前記EGCGの複合体を形成することと、ここで、混合された溶液から複合体が沈殿する、
前記複合体を含む持続放出性医薬製剤を調製することと
を含む、持続放出性医薬製剤を作成する方法。 - 医薬製剤が皮下に投与されるものであり、皮下投与のために適した医薬適合性の担体をさらに含む、請求項1に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56524704P | 2004-04-23 | 2004-04-23 | |
US60/565,247 | 2004-04-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509735A Division JP5036533B2 (ja) | 2004-04-23 | 2005-04-25 | 持続放出製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012046520A JP2012046520A (ja) | 2012-03-08 |
JP5829870B2 true JP5829870B2 (ja) | 2015-12-09 |
Family
ID=34967842
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509735A Expired - Fee Related JP5036533B2 (ja) | 2004-04-23 | 2005-04-25 | 持続放出製剤 |
JP2011196884A Pending JP2012036194A (ja) | 2004-04-23 | 2011-09-09 | 持続放出製剤 |
JP2011196883A Expired - Fee Related JP5829870B2 (ja) | 2004-04-23 | 2011-09-09 | 持続放出製剤 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509735A Expired - Fee Related JP5036533B2 (ja) | 2004-04-23 | 2005-04-25 | 持続放出製剤 |
JP2011196884A Pending JP2012036194A (ja) | 2004-04-23 | 2011-09-09 | 持続放出製剤 |
Country Status (16)
Country | Link |
---|---|
US (2) | US7323169B2 (ja) |
EP (1) | EP1750683B1 (ja) |
JP (3) | JP5036533B2 (ja) |
KR (1) | KR101201638B1 (ja) |
CN (2) | CN103920162B (ja) |
AU (1) | AU2005237542B2 (ja) |
CA (1) | CA2563185C (ja) |
DK (1) | DK1750683T3 (ja) |
ES (1) | ES2400687T3 (ja) |
HK (2) | HK1103023A1 (ja) |
IL (1) | IL178596A (ja) |
PL (1) | PL1750683T3 (ja) |
PT (1) | PT1750683E (ja) |
SI (1) | SI1750683T1 (ja) |
WO (1) | WO2005105057A1 (ja) |
ZA (1) | ZA200609401B (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005105057A1 (en) * | 2004-04-23 | 2005-11-10 | Amgen Inc. | Sustained release formulations |
US20050271726A1 (en) * | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
CA2589860A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
US7252834B2 (en) * | 2005-04-25 | 2007-08-07 | Clemson University Research Foundation (Curf) | Elastin stabilization of connective tissue |
CA2617859A1 (en) * | 2005-06-30 | 2007-01-11 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Glp-1 pharmaceutical compositions |
EP1993606A4 (en) * | 2006-02-15 | 2010-01-20 | Gammacan Ltd | VITILIGO PLASMA IMMUNOGLOBULINS FOR THE TREATMENT OF MELANOMA |
JP5410971B2 (ja) * | 2006-07-21 | 2014-02-05 | アムジエン・インコーポレーテツド | サンプル中のヘプシジンを検出および/または測定する方法 |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
CA2687141C (en) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
JP2011513220A (ja) * | 2008-02-21 | 2011-04-28 | ヴァトリックス・メディカル・インコーポレーテッド | デリバリービヒクルと組み合わせた結合組織安定剤の適用による動脈瘤の処置 |
US20100016833A1 (en) * | 2008-07-15 | 2010-01-21 | Ogle Matthew F | Devices for the Treatment of Vascular Aneurysm |
US20100119605A1 (en) * | 2008-11-12 | 2010-05-13 | Isenburg Jason C | Compositions for tissue stabilization |
US8444624B2 (en) | 2009-10-19 | 2013-05-21 | Vatrix Medical, Inc. | Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections |
US8911468B2 (en) | 2011-01-31 | 2014-12-16 | Vatrix Medical, Inc. | Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection |
KR20140145947A (ko) | 2011-03-16 | 2014-12-24 | 암젠 인크 | Nav1.3과 nav1.7의 유효한 선별적 저해제 |
EP2709711B8 (en) | 2011-05-18 | 2017-03-22 | Vatrix Medical, Inc. | Coated balloons for blood vessel stabilization |
EP2793925B1 (en) * | 2011-12-19 | 2019-03-20 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
ES2875957T3 (es) | 2012-12-20 | 2021-11-11 | Amgen Inc | Agonistas del receptor APJ y usos de los mismos |
JP2016508504A (ja) | 2013-02-01 | 2016-03-22 | サンタ マリア バイオセラピューティクス インコーポレイテッド | 対象に対する抗アクチビン−a化合物の投与 |
EP2970408B1 (en) | 2013-03-12 | 2018-01-10 | Amgen Inc. | Potent and selective inhibitors of nav1.7 |
CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
EP3634507A4 (en) * | 2017-06-07 | 2021-03-24 | EGY-Nano Pharma, LP | PROLONGED ORAL DRUG DELIVERY PLATFORMS |
KR20210080349A (ko) | 2018-08-03 | 2021-06-30 | 넥테로 메디칼, 인크. | 정제된 펜타갈로일 글루코스 및 전달용 장치 |
WO2020227437A1 (en) | 2019-05-06 | 2020-11-12 | Axial Biotherapeutics, Inc. | Sustained release solid dosage forms for modulating the colonic microbiome |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
GB929405A (en) | 1958-12-22 | 1963-06-19 | Upjohn Co | Processes for the encapsulation of particles |
CH498653A (fr) | 1968-03-29 | 1970-11-15 | Kobayashi Takehiko | Procédé d'encapsulation de matières hydrophobes |
GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US5151265A (en) * | 1987-11-03 | 1992-09-29 | Genentech, Inc. | Gamma interferon formulation |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
WO1994008599A1 (en) * | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
JP2744572B2 (ja) * | 1993-02-17 | 1998-04-28 | 鐘紡株式会社 | ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法 |
JPH06345668A (ja) * | 1993-06-07 | 1994-12-20 | Shibayagi:Kk | 感染防御組成物およびその用途 |
US5922253A (en) * | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
EP0850051A2 (en) * | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
AU4414497A (en) | 1996-09-13 | 1998-04-02 | University Technology Corporation | Biocompatible cationic detergents and uses therefor |
US20030190307A1 (en) * | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
US6531154B1 (en) * | 1997-06-10 | 2003-03-11 | Brown University Research Foundation | Modulated release from biocompatible polymers |
HUP0002490A2 (hu) * | 1997-07-23 | 2000-12-28 | Perio Products Ltd. | Csersav-polimer kompozíciók gyógyászati anyagok szabályozott leadására, különösen a szájüregben |
US6180666B1 (en) | 1997-09-05 | 2001-01-30 | Anmax, Inc. | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
US5962522A (en) * | 1997-09-05 | 1999-10-05 | Avmax, Inc. | Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds |
US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
JP2002512182A (ja) * | 1998-04-20 | 2002-04-23 | ジェンザイム・コーポレーション | ポリマーブレンドから蛋白質のドラックデリバリー |
JP2000080027A (ja) * | 1998-09-02 | 2000-03-21 | Taiyo Kagaku Co Ltd | 徐放性製剤 |
US6428818B1 (en) * | 1999-03-30 | 2002-08-06 | Purdue Research Foundation | Tea catechin formulations and processes for making same |
CA2389304A1 (en) | 1999-11-01 | 2001-05-10 | Corinne S. Lengsfeld | Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing |
US6713506B2 (en) * | 2000-10-11 | 2004-03-30 | University Of South Florida | Tea polyphenol esters and analogs thereof for cancer prevention and treatment |
WO2002067966A1 (en) * | 2001-02-22 | 2002-09-06 | Purdue Research Foundation | Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer |
JP5013152B2 (ja) * | 2001-02-28 | 2012-08-29 | 株式会社ビーエムジー | 蛋白質複合体形成剤 |
US20040142048A1 (en) * | 2002-02-22 | 2004-07-22 | Morre Dorothy M. | Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer |
WO2004012522A1 (en) * | 2002-07-26 | 2004-02-12 | Dsm Ip Assets B.V. | Compositions comprising lactoferrin |
US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US7605120B2 (en) * | 2003-10-22 | 2009-10-20 | Amgen Inc. | Antagonists of the brandykinin B1 receptor |
WO2005105057A1 (en) * | 2004-04-23 | 2005-11-10 | Amgen Inc. | Sustained release formulations |
-
2005
- 2005-04-25 WO PCT/US2005/014254 patent/WO2005105057A1/en active Application Filing
- 2005-04-25 ES ES05742315T patent/ES2400687T3/es active Active
- 2005-04-25 SI SI200531678T patent/SI1750683T1/sl unknown
- 2005-04-25 PL PL05742315T patent/PL1750683T3/pl unknown
- 2005-04-25 EP EP05742315A patent/EP1750683B1/en active Active
- 2005-04-25 DK DK05742315.4T patent/DK1750683T3/da active
- 2005-04-25 JP JP2007509735A patent/JP5036533B2/ja not_active Expired - Fee Related
- 2005-04-25 PT PT57423154T patent/PT1750683E/pt unknown
- 2005-04-25 US US11/114,473 patent/US7323169B2/en not_active Expired - Fee Related
- 2005-04-25 AU AU2005237542A patent/AU2005237542B2/en not_active Ceased
- 2005-04-25 KR KR1020067021346A patent/KR101201638B1/ko not_active IP Right Cessation
- 2005-04-25 CN CN201410023256.4A patent/CN103920162B/zh not_active Expired - Fee Related
- 2005-04-25 CA CA2563185A patent/CA2563185C/en not_active Expired - Fee Related
- 2005-04-25 CN CNA2005800124592A patent/CN1997356A/zh active Pending
-
2006
- 2006-10-15 IL IL178596A patent/IL178596A/en not_active IP Right Cessation
- 2006-11-13 ZA ZA200609401A patent/ZA200609401B/en unknown
-
2007
- 2007-08-13 HK HK07108780.0A patent/HK1103023A1/xx not_active IP Right Cessation
- 2007-08-30 US US11/847,984 patent/US7732399B2/en not_active Expired - Fee Related
-
2011
- 2011-09-09 JP JP2011196884A patent/JP2012036194A/ja active Pending
- 2011-09-09 JP JP2011196883A patent/JP5829870B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-16 HK HK15100510.4A patent/HK1200092A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2012046520A (ja) | 2012-03-08 |
CA2563185C (en) | 2010-04-20 |
US20050271722A1 (en) | 2005-12-08 |
US7323169B2 (en) | 2008-01-29 |
DK1750683T3 (da) | 2013-04-15 |
ZA200609401B (en) | 2008-05-28 |
AU2005237542A1 (en) | 2005-11-10 |
SI1750683T1 (sl) | 2013-04-30 |
HK1200092A1 (en) | 2015-07-31 |
PT1750683E (pt) | 2013-01-25 |
CA2563185A1 (en) | 2005-11-10 |
JP5036533B2 (ja) | 2012-09-26 |
EP1750683B1 (en) | 2013-01-09 |
AU2005237542B2 (en) | 2009-12-17 |
CN1997356A (zh) | 2007-07-11 |
JP2012036194A (ja) | 2012-02-23 |
KR101201638B1 (ko) | 2012-11-15 |
IL178596A0 (en) | 2007-02-11 |
CN103920162B (zh) | 2017-07-11 |
ES2400687T3 (es) | 2013-04-11 |
IL178596A (en) | 2012-06-28 |
US20070292506A1 (en) | 2007-12-20 |
PL1750683T3 (pl) | 2013-05-31 |
EP1750683A1 (en) | 2007-02-14 |
CN103920162A (zh) | 2014-07-16 |
US7732399B2 (en) | 2010-06-08 |
KR20070026457A (ko) | 2007-03-08 |
JP2007534698A (ja) | 2007-11-29 |
WO2005105057A1 (en) | 2005-11-10 |
HK1103023A1 (en) | 2007-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5829870B2 (ja) | 持続放出製剤 | |
KR101337797B1 (ko) | 지속형 인간 성장 호르몬 결합체 액상 제제 | |
JP5774828B2 (ja) | ペプチドおよびタンパク質の薬学的因子の精製および安定化 | |
AU2003257156B2 (en) | Cell transport compositions and uses thereof | |
KR101340710B1 (ko) | 지속형 과립구 콜로니 자극인자 결합체의 액상 제제 | |
US20150290132A1 (en) | Cell Transport Compositions and Uses Thereof | |
KR101303388B1 (ko) | 지속형 인터페론 알파 결합체의 액상 제제 | |
PL215168B1 (pl) | Formulacja polipeptydowa | |
TW201004649A (en) | A polypeptide complex comprising non-peptidyl polymer having three functional ends | |
JP2019511497A (ja) | エキセナチド類似体の持続放出コンジュゲート | |
KR20050026414A (ko) | 단기 저장형 제형 | |
KR102364521B1 (ko) | 알부민 및 폴리에틸렌글리콜을 포함하는 하이드로겔 및 그의 제조방법 | |
MXPA06012009A (es) | Formulaciones de liberacion prolongada | |
WO2023220690A1 (en) | Transient sirolimus with fasl microgels | |
JP6527697B2 (ja) | タンパク質を安定化させたゲル状製剤 | |
US20180125791A1 (en) | Polymer nanocapsules for protein delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130801 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140604 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140814 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140912 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150414 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151023 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5829870 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |